Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 127

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9C
Chunk 127
---
 sunglass maker Prive Revaux (March 2018 to April 2020),
curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December
2012 to March 2016). Mr. MacPherson holds a BA in Economics from Gettysburg College. Mr. MacPherson also serves as a director of MIRA
Pharmaceuticals, Inc. (Nasdaq:MIRA)

Key
Advisor 

Dr.
Itzchak Angel, has served as our Chief Scientific Advisor to the Company since August, 2024. Since 2005, Dr. Angel has been the President and CEO
of Angel Pharmaceuticals Consulting & Technologies where he assists pharmaceutical and biotechnology companies, individuals, medical
staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development.
In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of
clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors,
and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development
process–from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business
development, and organizational planning. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France)
where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine).
Some of Dr. Angel’s previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa,
Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot,
Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’
Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancer. He received a B.Sc. degree from Tel-Aviv University
in 1979 and earned his M.Sc degree from Tel-Aviv University in 1980, both in biology. He further studied at the Hamburg University, Germany,
obtaining